How can we ensure that groundbreaking medical innovations reach patients without being held back by outdated pricing models?
This was the question our consortium member Mark Nuijten (A2M) brought to the European Biotechnology Congress in Tirana, held from 11–13 September. On this international stage, he introduced POC4TRIAGE and presented the Integrated Valuation Model, a fresh approach to assessing the true value of medical innovations.
The model goes beyond traditional cost-effectiveness ratios, demonstrating how therapies and digital health solutions can be priced fairly while ensuring patient access and financial sustainability. Already applied in the Netherlands and Belgium, it paves the way for more transparent and equitable reimbursement policies. By sharing these insights, our consortium contributes to rethinking how health systems worldwide can support innovation that matters.